PAVmed (NASDAQ:PAVM) Upgraded to Hold at Wall Street Zen

PAVmed (NASDAQ:PAVM) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also commented on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of PAVmed in a research note on Thursday, January 22nd. Ascendiant Capital Markets lowered their price target on PAVmed from $600.00 to $510.00 and set a “buy” rating on the stock in a research note on Wednesday, December 10th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $510.00.

PAVmed Price Performance

PAVM stock opened at $9.85 on Friday. The stock has a market capitalization of $9.85 million, a P/E ratio of -0.43 and a beta of 0.81. The firm has a 50-day simple moving average of $9.90 and a 200-day simple moving average of $10.61. PAVmed has a 52 week low of $6.00 and a 52 week high of $28.44.

Institutional Trading of PAVmed

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC raised its holdings in PAVmed Inc. (NASDAQ:PAVM) by 392.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 52,676 shares of the company’s stock after acquiring an additional 41,990 shares during the period. Jane Street Group LLC owned approximately 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. Institutional investors own 19.93% of the company’s stock.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.